Shopping Cart 0
Cart Subtotal
USD 0

Swedish Orphan Biovitrum AB (SOBI) - Financial and Strategic SWOT Analysis Review

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 125

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 250

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 375
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Swedish Orphan Biovitrum AB (SOBI) Financial and Strategic SWOT Analysis Review provides you an in depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description A detailed description of the company's operations and business divisions.

Corporate strategy Analyst's summarization of the company's business strategy.

SWOT Analysis A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history Progression of key events associated with the company.

Major products and services A list of major products, services and brands of the company.

Key competitors A list of key competitors to the company.

Key employees A list of the key executives of the company.

Executive biographies A brief summary of the executives' employment history.

Key operational heads A list of personnel heading key departments/functions.

Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.

Key manufacturing facilities A list of key manufacturing facilities of the company.

Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semi annual financial statements published by the company for 5 interims history.

Highlights

Swedish Orphan Biovitrum AB (Sobi), formerly Biovitrum AB, is an integrated biopharmaceutical company that focuses on the development of products for the treatment of rare diseases. The company specializes in biotechnology with prime capabilities in protein biochemistry and biologics manufacturing. Its product portfolio focuses on haemophilia, inflammation and genetic and metabolic diseases. The company's products include Alprolix, Ammonaps, Elocta, Kepivance, Kineret and Orfadin. Sobi also manufactures and markets specialty and rare disease products for partner companies. It has operational presence in Europe, the Middle East and North Africa. Sobi is headquartered in Stockholm, Sweden.

Swedish Orphan Biovitrum AB Key Recent Developments

Apr 26,2018: Sobi publishes the report for the first quarter 2018

Apr 17,2018: Sobi publishes 2017 Annual and Sustainability Report

Apr 03,2018: Fredrik Wetterlundh joins Sobi as Head of Human Resources

Feb 28,2018: Sobi Launches Enhanced Corporate Sustainability Initiative

Feb 26,2018: Swedish Orphan Biovitrum Appoints Henrik Stenqvist As New Chief Financial Officer

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1 About the Company 6

Swedish Orphan Biovitrum AB Key Facts 6

Swedish Orphan Biovitrum AB Key Employees 7

Swedish Orphan Biovitrum AB Key Employee Biographies 8

Swedish Orphan Biovitrum AB Major Products and Services 9

Swedish Orphan Biovitrum AB History 10

Swedish Orphan Biovitrum AB Company Statement 16

Swedish Orphan Biovitrum AB Locations And Subsidiaries 17

Head Office 17

Other Locations & Subsidiaries 17

Section 2 Company Analysis 19

Company Overview 19

Swedish Orphan Biovitrum AB Business Description 20

Business Segment: Haemophilia 20

Overview 20

Performance 20

Business Segment: ReFacto 20

Overview 20

Performance 20

Business Segment: Specialty Care 21

Overview 21

Performance 21

Geographical Segment: Europe 21

Performance 21

Geographical Segment: MENAR 21

Performance 21

Geographical Segment: North America 21

Performance 21

Geographical Segment: Rest of World 21

Performance 21

Swedish Orphan Biovitrum AB SWOT Analysis 22

SWOT Analysis Overview 22

Swedish Orphan Biovitrum AB Strengths 22

Swedish Orphan Biovitrum AB Weaknesses 23

Swedish Orphan Biovitrum AB Opportunities 24

Swedish Orphan Biovitrum AB Threats 25

Swedish Orphan Biovitrum AB Key Competitors 26

Section 3 Company Financial Ratios 27

Financial Ratios Capital Market Ratios 27

Financial Ratios Annual Ratios 28

Performance Chart 31

Financial Performance 31

Financial Ratios Interim Ratios 32

Financial Ratios Ratio Charts 33

Section 4 Company's Lifesciences Financial Deals and Alliances 34

Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 34

Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 35

Swedish Orphan Biovitrum AB, Recent Deals Summary 36

Section 5 Company's Recent Developments 37

Apr 26, 2018: Sobi publishes the report for the first quarter 2018 37

Apr 17, 2018: Sobi publishes 2017 Annual and Sustainability Report 38

Apr 03, 2018: Fredrik Wetterlundh joins Sobi as Head of Human Resources 39

Feb 28, 2018: Sobi Launches Enhanced Corporate Sustainability Initiative 40

Feb 22, 2018: Sobi publishes its report for the fourth quarter and full year 2017 42

Feb 07, 2018: The Republic of Ireland Switches all People With Haemophilia A & B Treated With Replacement Clotting Factors to Sobi's Extended Half life Therapies 43

Feb 07, 2018: Time to Elevate Protection in Haemophilia Care: New Data From Sobi 44

Oct 25, 2017: Sobi publishes its report for the third quarter 2017 45

Oct 24, 2017: Sobi establishes new leadership structure and appoints Torbjorn Hallberg as General Counsel 46

Oct 06, 2017: Norbert Oppitz joins Sobi as new Senior Vice President, Specialty Care 47

Section 6 Appendix 48

Methodology 48

Ratio Definitions 48

About GlobalData 52

Contact Us 52

Disclaimer 52


List Of Figure

List of Figures

Swedish Orphan Biovitrum AB, Performance Chart (2013 2017) 31

Swedish Orphan Biovitrum AB, Ratio Charts 33

Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 34

Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 35


List Of Table

List of Tables

Swedish Orphan Biovitrum AB, Key Facts 6

Swedish Orphan Biovitrum AB, Key Employees 7

Swedish Orphan Biovitrum AB, Key Employee Biographies 8

Swedish Orphan Biovitrum AB, Major Products and Services 9

Swedish Orphan Biovitrum AB, History 10

Swedish Orphan Biovitrum AB, Subsidiaries 17

Swedish Orphan Biovitrum AB, Key Competitors 26

Swedish Orphan Biovitrum AB, Ratios based on current share price 27

Swedish Orphan Biovitrum AB, Annual Ratios 28

Swedish Orphan Biovitrum AB, Annual Ratios (Cont...1) 29

Swedish Orphan Biovitrum AB, Annual Ratios (Cont...2) 30

Swedish Orphan Biovitrum AB, Interim Ratios 32

Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 34

Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 35

Swedish Orphan Biovitrum AB, Recent Deals Summary 36

Currency Codes 48

Capital Market Ratios 48

Equity Ratios 49

Profitability Ratios 49

Cost Ratios 50

Liquidity Ratios 50

Leverage Ratios 51

Efficiency Ratios 51

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Swedish Orphan Biovitrum AB, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

Slottsviken Fastighetsaktiebolag

Oasmia Pharmaceutical AB

New Nordic Healthbrands AB

Hansa Medical AB

Fastilium Property Group AB

BioGaia AB

AMAG Pharmaceuticals Inc